Biogen Inc. (BIIB) is in the spotlight, with reports suggesting a mixture of gains and challenges. The company saw lower-than-expected revenue growth and is dealing with a securities fraud lawsuit. The Phase 1/2 study results of an investigational drug for Amyotrophic Lateral Sclerosis have been announced but a prominent investor, Mirae Asset Global Investments Co. Ltd., sold a significant portion of its shares. Biogen has faced class action lawsuits, however, its Q1 2024 earnings came in above expectations. Biogen is said to be realigning resources for its Alzheimer's Disease Franchise and gained EU approval for its rare disease drug, Qalsody. A partner has begun filing for its Leqembi SC autoinjector. A downturn in sales has been reported amidst the high costs of its Alzheimer's drug, Aduhelm. Emblematic of future growth, Biogen is looking to acquire HI-Bio to expand its rare disease pipeline, and looking to sell its stake in a biosimilar joint venture to Samsung Biologics.
Biogen BIIB News Analytics from Fri, 28 Jul 2023 07:00:00 GMT to Sun, 07 Jul 2024 18:36:45 GMT - Rating -2 - Innovation -1 - Information 2 - Rumor -4
